Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products

Sonoma Pharmaceuticals, Inc.

Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.
Initial 2-year term auto-renewing; royalty on Net Sales (percentage redacted) due quarterly.
Marketing through Sonoma's existing EU distribution network; NovaBay retains rights outside territories.
NovaBay represents it owns the marks, but applications in EU are still pending as previously disclosed.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sonoma Pharmaceuticals, Inc. entered into a license with NovaBay Pharmaceuticals, Inc. (effective 2024-01-05).

Action: entry
Agreement: license
Counterparty: NovaBay Pharmaceuticals, Inc.
Effective: 2024-01-05

Exact text from the filing

Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova ® -branded products by the Company in the European Union.

View on SEC.gov

822 material agreements filed in the last 30 days. Browse all material agreements →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-000150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.